Skip to main content
Article
Atazanavir Sulfate. Fresh from the Pipeline
Nature Reviews Drug Discovery
  • Aarti Raja, Nova Southeastern University
  • J. Lebbos
  • P. Kirkpatrick
Document Type
Article
Publication Date
11-1-2003
Disciplines
Abstract

In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?

Citation Information
Aarti Raja, J. Lebbos and P. Kirkpatrick. "Atazanavir Sulfate. Fresh from the Pipeline" Nature Reviews Drug Discovery (2003) ISSN: 1474-1776
Available at: http://works.bepress.com/aarti-raja/7/